Searched for
CIPLA PEPTIDE PORTFOLIO
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Cipla Q2 Results: Net profit grows 4% YoY to Rs 1,351 crore; revenue rises 8%Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company s...
- Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ crCipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...
- Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COOEris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...
- Cipla shares rally 6% in 2 days as Q1 results impress; brokerages raise target up to Rs 1,875Cipla shares: Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates re...
- Obesity lab: India becomes ground zero for weight-loss drug raceIndia is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expi...
- Cipla Q1 Results: Cons PAT rises 18% YoY to Rs 1,178 crore, beats estimatesCipla Q1 Results: The profit beat the ET Now Poll estimates of Rs 1,071 crore. Revenue from operations in the reporting period increased 6%...
- Fundamental Radar: Why is Cipla a top pick in the pharma space for Motilal Oswal? Sneha Poddar explainsOn the India business front, in particular, Cipla is working to not only enhance its prescription base but also strengthen its trade generi...
- Cipla Q2 Results: Profit jumps 43% YoY to Rs 1,131 crore, revenue rises 15%The bottomline was higher than the Rs 1,006 crore which was expected by analysts in an ET Now poll. Cipla's consolidated margin came in at ...
- Outlook on healthcare sector; Cipla & Sun Pharma could give 15-20% returnANDA approval rate has been on a steady rise post-COVID, from the low of 540 in CY21 to ~700+ annual approvals in CY23E, backed by a reduct...
- Blackstone sets its sights on buying out Hamieds from CiplaNon-binding bid likely next week for 33.4% stake, will trigger open offer for 26% more. At current mkt value deal size could be over $6 bn ...
- Buy Cipla, target price Rs 1260: Axis SecuritiesCipla, incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 86522.68 Crore) operating in Pharmaceuticals sector.
- Why Nithya Balasubramanian is gung-ho on Sun Pharma & Cipla“One gets different types of exposure with Sun Pharma and Cipla. For Sun, the capital allocation into US specialty is now bearing fruit. At...
- Cipla betting big on digitisation and emerging segmentsThe drug firm has embarked on the digital transformation of the value chain across functions, including finance, R&D, manufacturing, supply...
- Cipla skids 4% on Jan-Mar earnings missThe total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quar...
- Cipla Q4 Results: Profit falls 12.4% YoY to Rs 362 cr, misses estimatesThe total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quar...
- Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was made possi...
- Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was possible b...
- Most brokerages bullish on Cipla; cite US, local market growth potentialMost brokerages maintained a bullish view on Cipla citing the pharmaceutical major's healthy pipeline of product launches in the United Sta...
Load More
